Three Dermalax boxes can look like three equal purchasing units. They are not. Plus and Deep Plus each contain one 1.1 mL syringe, while Implant Plus contains two. At the same time, the manufacturer reports a clear G’ progression across the line. That makes Dermalax both a product-selection decision and an inventory-math decision—and the two should not be confused.
Quick answer
Dermalax Plus, Deep Plus and Implant Plus form a compact three-step range with manufacturer-reported G’ values of 80 ± 15, 160 ± 15 and 280 ± 15 Pa. Plus contains 20 mg/mL HA; Deep Plus and Implant Plus contain 24 mg/mL. The commercial difference is just as important: the first two come with one syringe per box, while Implant Plus comes with two. A clinic should therefore choose the product role first, then compare live price per syringe—not box price alone.
Read the Dermalax line as two decisions, not one
A simple “lighter, medium, stronger” chart misses the clinic decision. First define which published position fits established services; then count how many stock units that choice creates.
Plus, Deep Plus and Implant Plus occupy distinct positions in the manufacturer’s published elasticity ladder.
The pack doubles only at Implant Plus, so the number of SKUs and the number of syringes are not the same.
HA concentration does not solve the first decision. Deep Plus and Implant Plus both list 24 mg/mL, yet their published G’ values, supplied needle gauges and pack quantities differ. Box price does not solve the second decision either, because a two-syringe box should not be compared directly with a one-syringe box.
Dermalax Plus, Deep Plus and Implant Plus at a glance
| Product | G’ from manufacturer brochure | HA | Lidocaine | Supplied format | Useful clinic reading |
|---|---|---|---|---|---|
| Dermalax Plus | 80 ± 15 Pa | 20 mg/mL | 0.3% | 1 × 1.1 mL 2 × 30G needles | Lowest-G’ position and the smallest one-box stock commitment |
| Dermalax Deep Plus | 160 ± 15 Pa | 24 mg/mL | 0.3% | 1 × 1.1 mL 2 × 27G needles | Middle position and the simplest single-SKU entry point |
| Dermalax Implant Plus | 280 ± 15 Pa | 24 mg/mL | 0.3% | 2 × 1.1 mL 4 × 25G needles | Highest-G’ position with twice the syringes per box |
The “useful clinic reading” column is Cytollia’s purchasing interpretation of the published product data, not a treatment protocol or a good-better-best ranking.
Deep Plus vs Implant Plus: same concentration, different decision
Deep Plus and Implant Plus are the comparison most likely to be oversimplified. Both contain 24 mg/mL HA and 0.3% lidocaine, and each syringe holds 1.1 mL. If concentration and syringe volume were the only fields shown, the products could look almost interchangeable.
They are not. The manufacturer brochure places Deep Plus at 160 ± 15 Pa G’ and Implant Plus at 280 ± 15 Pa. Across also supplies them with different needle gauges, and Implant Plus doubles the box quantity. The range therefore changes in both product behavior and purchasing commitment.
A practical way to introduce Dermalax when the clinic wants one central SKU, one syringe per box and a low opening-unit commitment.
A different stock decision for clinics with recurring demand for the upper position and enough turnover to use a two-syringe pack efficiently.
Implant Plus is not “better” because its G’ is higher, and Deep Plus is not a discounted version of Implant Plus. The useful question is which position the clinic needs—and whether one or two syringes is the right commercial unit for that demand.
The box-price illusion
Plus and Deep Plus each contain one syringe, while Implant Plus contains two. A box-level comparison can therefore make Implant Plus look disproportionately expensive even when its live per-syringe cost is similar to the other products.
Normalize the unit before comparing the price.
- Dermalax Plus box price ÷ 1 syringe
- Dermalax Deep Plus box price ÷ 1 syringe
- Dermalax Implant Plus box price ÷ 2 syringes
The product pages linked below show current prices and tier information. Compare those figures per syringe, then decide whether every unit in the box can turn over.
The commercial conclusion is simple: a higher box price does not necessarily mean a higher unit price. The cheapest unused syringe is still excess stock.
Four practical ways to stock the range
A complete shelf is not automatically a useful shelf. Dermalax can be introduced in stages, with each addition answering a visible gap in the clinic’s services or reorder history.
Deep Plus only
The smallest way to test the family through its middle published position.
Plus + Deep Plus
Two distinct G’ positions with one syringe in each opening box.
Deep Plus + Implant Plus
Two positions, with two of the three stock units concentrated in Implant Plus.
Plus + Deep Plus + Implant Plus
One box of every product creates four syringes, not three.
The opening order should follow services the clinic already sells, not the appeal of a complete shelf. Start with the position most likely to turn over, record use by SKU, and expand when consultations reveal a recurring gap.
What makes Dermalax different inside the Across portfolio
Dermalax’s mixed pack structure is not an inevitable feature of a three-step filler family. Across’s current Revolax page lists Fine, Deep and Sub-Q with one syringe per box. Its Chaeum Premium No.1–No.4 page lists two syringes for every number. Dermalax sits between those models: one syringe for Plus, one for Deep Plus and two for Implant Plus.
3 variants
1 · 1 · 1 syringes
4 variants
2 · 2 · 2 · 2 syringes
3 variants
1 · 1 · 2 syringes
That gives Dermalax a specific commercial signature within the same manufacturer’s portfolio. A clinic can trial either of the first two positions one syringe at a time, while the upper position arrives as a two-unit commitment.
Implant Plus has more than a packaging story
A product-specific clinical proof point
A 2017 randomized, multicentre, patient/evaluator-blind matched-pair study enrolled 52 subjects and compared Dermalax Implant Plus with Restylane Sub-Q for nasolabial-fold correction. At 24 weeks, Implant Plus met the study’s non-inferiority conclusion; the investigators also reported lower immediate pain scores on the side treated with the lidocaine-containing Dermalax product than on the comparator side, which did not contain incorporated lidocaine.
That evidence belongs to Implant Plus and the studied correction task. Its value here is precise: the upper Dermalax SKU has direct published clinical data, rather than being defined only by its name, G’ value and larger box.
Make the purchasing decision in this order
- Define the missing clinic role. Decide whether the service mix needs the lower, middle or upper published position before looking at price.
- Read G’ with the whole product profile. Do not use HA concentration alone to separate Deep Plus from Implant Plus.
- Count syringes, not just SKUs. One box of each Dermalax product creates four inventory units.
- Normalize live cost. Compare price per syringe and current tier pricing, then check whether pack quantity matches expected turnover.
- Reorder from actual use. Let SKU-level demand earn the next box instead of maintaining a complete family for appearance.
Results, duration and the client conversation
Dermalax products are temporary crosslinked HA fillers. A visible change may be apparent immediately, while early swelling can alter the first impression. The Implant Plus study measured outcomes through 24 weeks, but it should not be converted into one duration promise for every Dermalax variant. Product choice, treatment area, tissue movement, treatment plan and individual response all influence persistence.
For clients, the cleanest explanation is that the clinic chooses from different positions within one product family after professional assessment. The client does not need to select a syringe from a stiffness chart; the chart helps the clinic organize product roles, consultation language and stock.
Dermalax FAQ for clinics
What is the main difference between Dermalax Plus, Deep Plus and Implant Plus?
The manufacturer reports a G’ progression of 80 ± 15, 160 ± 15 and 280 ± 15 Pa. HA concentration is 20, 24 and 24 mg/mL. Plus and Deep Plus contain one syringe per box; Implant Plus contains two.
Is Implant Plus twice as expensive as Deep Plus?
Do not judge from box price alone. Deep Plus contains one syringe and Implant Plus contains two, so current prices must be normalized per syringe before drawing a commercial conclusion.
Which Dermalax product should a clinic stock first?
There is no universal first choice. Deep Plus is the simplest single-SKU middle entry, but an existing service mix may justify Plus or Implant Plus first. Choose the missing product role, then check whether the box quantity fits expected turnover.
Is Implant Plus the “strongest” Dermalax?
It has the highest manufacturer-reported G’ of the three current Cytollia products. Higher G’ describes a different elastic position; it does not make Implant Plus the best choice for every client or treatment goal.
Do all three Dermalax products contain lidocaine?
Yes. Across lists 0.3% lidocaine for Plus, Deep Plus and Implant Plus.
Who manufactures Dermalax?
Dermalax is manufactured by Across in South Korea. Across also publishes the Revolax and Chaeum product families referenced above.
Choose the role. Then check the live unit economics.
Use the current product pages to compare availability and tier pricing. The clinic decision begins with the product position, but the purchase decision should finish with current cost per syringe and the number of units the box adds to stock.
Dermalax Plus
1 × 1.1 mL · 20 mg/mL HA
View product & live pricingDermalax Deep Plus
1 × 1.1 mL · 24 mg/mL HA
View product & live pricingDermalax Implant Plus
2 × 1.1 mL · 24 mg/mL HA
View product & live pricingCommercial disclosure: Cytollia sells the products linked above. Product facts are drawn from manufacturer materials and the cited clinical paper; prices and availability update on the product pages.
Sources
- Across — Dermalax product specifications
- Across/Hugel technical brochure — Dermalax and The Chaeum
- Across — Revolax product and pack specifications and Across — Chaeum product and pack specifications
- Suh et al. — Dermalax Implant Plus randomized multicentre study, Journal of Cosmetic Dermatology (2017)
Last verified: 24 July 2026. Professional-use editorial content. Product selection and treatment remain the responsibility of appropriately qualified practitioners using current local product information.